✓ Medically Reviewed Monograph

Hydroxychloroquine Sulfate

Also known as / Synonyms: HCQ, Hydroxychloroquine, 4-Aminoquinoline DMARD

Essential disease-modifying tablet that controls lupus flares, calms rheumatoid arthritis, and protects internal organs.

🩺
Reviewed by Dr. Lisa M., PharmD
Chief Clinical Editor · Updated November 19, 2026 · Editorial & Fact-Checking Policy
CDSCO & FDA Aligned
📋

Clinical Snapshot & Specifications

Generic Name: Hydroxychloroquine Sulfate
Active Ingredient: Hydroxychloroquine Sulfate
Dosage Form: Tablet
Available Strengths: 200 mg, 300 mg, 400 mg film-coated tablets
Prescription Status: Prescription only (Schedule H / verified)
Approved Routes:
Oral
Popular Verified Brands:
HCQS Plaquenil Hydroquin Zy-Q (India)
Regulatory Standards: Approved by CDSCO; Schedule H prescription drug in India. First-line fundamental therapy for systemic lupus erythematosus on the WHO Model List.
🎯

Approved Indications & Medical Uses

  • Treatment of systemic lupus erythematosus (SLE) in adults and pediatric patients (reduces disease flares, organ damage, and mortality).
  • Treatment of active rheumatoid arthritis (alone or as part of triple DMARD therapy with methotrexate and sulfasalazine).
  • Treatment of chronic discoid lupus erythematosus.
  • Prophylaxis and treatment of uncomplicated malaria caused by Plasmodium vivax, P. malariae, P. ovale, and susceptible P. falciparum.
🚫

Contraindications (Do Not Use If…)

  • Known hypersensitivity to 4-aminoquinoline compounds.
  • Pre-existing retinopathy or maculopathy of the eye (retinal toxicity is irreversible).
  • Long-term therapy in pediatric patients.
🛡️

Important Clinical Precautions & Warnings

  • Irreversible retinal toxicity (Bull's eye maculopathy): binds to melanin in the retinal pigment epithelium, causing irreversible maculopathy and central vision loss; baseline ophthalmologic examination (visual fields, OCT) required within the first year, followed by annual screening after 5 years of therapy (or earlier if high-risk).
  • Maximum daily dose ceiling: calculate daily dose based on actual body weight; do not exceed 5.0 mg/kg/day of actual weight to minimize retinal toxicity risk.
  • Cardiomyopathy and conduction disorders: fatal cardiomyopathy and conduction blocks (bundle branch block, AV block) reported with chronic high-dose therapy; perform periodic ECG.
  • Take with food or milk: reduces nausea, stomach cramps, and gastrointestinal discomfort.
  • Hypoglycemia: can cause severe hypoglycemia even in non-diabetic patients; monitor blood glucose.
  • QTc prolongation: can prolong the QT interval, especially in patients with cardiac disease or co-prescribed arrhythmogenic drugs.

Special Populations (Paediatric & Geriatric Care)

Pediatric: Approved for pediatric lupus; weight-based dosing (3 to 5 mg/kg/day); not recommended for prolonged pediatric RA. Geriatric: Safe; calculate dose based strictly on actual body weight (<= 5 mg/kg/day) and monitor renal function.

⚡

Side Effects & Adverse Reactions

ℹ️ Common Side Effects (Usually Mild)

Nausea, diarrhea, abdominal cramps, headache, dizziness, anorexia, mild skin rash, and bleaching of hair.

🚨 Serious Side Effects — Seek Urgent Medical Care

Irreversible Bull's eye retinal maculopathy and permanent visual field defects, restrictive cardiomyopathy, conduction heart block, severe hypoglycemia, agranulocytosis, and toxic epidermal necrolysis.

Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.

🔄

Drug, Food & Substance Interactions

  • Digoxin: hydroxychloroquine elevates serum digoxin levels; monitor digoxin concentrations closely.
  • Insulin and oral antidiabetic agents: enhances hypoglycemic effect; may require dose reduction of antidiabetic drugs.
  • Other QT-prolonging agents (amiodarone, moxifloxacin): additive risk of ventricular arrhythmias.
  • Antacids: magnesium and aluminum antacids reduce HCQ absorption; separate administration by 4 hours.
🤰

Pregnancy & Lactation Clinical Safety

Pregnancy Safety:

Hydroxychloroquine is the disease-modifying drug of choice during pregnancy in women with systemic lupus erythematosus. Extensive international registry data show that continuing HCQ reduces pregnancy complications (lupus flares, preeclampsia, congenital heart block) without increasing congenital anomalies.

Lactation & Breastfeeding:

Excreted into breast milk in small amounts. Long-term studies show no adverse visual or hearing effects in nursing infants. It is considered safe and compatible with breastfeeding in lupus patients.

📦

Storage, Administration & Overdose Protocol

🌡️ Recommended Storage:

Store tablets at 20°C to 25°C (68°F to 77°F). Protect from light and moisture.

⏱️ Missed Dose Protocol:

Take the missed dose with meals as soon as remembered on that day. If close to the next scheduled dose, skip and resume regular schedule. Do not take a double dose.

🛡️
Clinical & Legal Disclaimer: The clinical monographs and drug information published on 4mg.in are strictly intended for educational, clinical reference, and informational utility. They do not constitute personalized medical advice, diagnosis, or treatment regimens. Always seek the advice of a registered physician or licensed pharmacist regarding specific clinical conditions, prescription dosages, and potential contraindications. Review our comprehensive Editorial & Clinical Fact-Checking Policy.